HPV HR, Screening 14 Types + Sample Adequacy Control (Urogenital Tract Scraping)
Test for detecting high oncogenic risk HPV DNA (14 types) in urogenital tract epithelial cells by PCR in screening format. Used for early detection of HPV infection, assessment of precancerous and oncological change risk, preventive examination, and dynamic monitoring. Includes sample adequacy control.
Biomaterial: Urogenital tract epithelial cell scraping
Avoid sexual contact for 24-48 hours; do not use local medications, douching, or antiseptics; submission outside menstruation is recommended; avoid invasive procedures before collection.
Preventive examination of women and men; Pap test abnormalities; suspected urogenital tract HPV infection; monitoring after HPV treatment; preparation for pregnancy or planned medical interventions.
Negative — high oncogenic risk HPV DNA not detected, sample adequacy control normal.
Positive — high oncogenic risk HPV DNA detected, physician consultation and additional examination required.
Important: a positive screening result does not mean presence of oncological disease.
